enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Increase in Short Interest

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 67,300 shares, an increase of 80.9% from the March 31st total of 37,200 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 81,500 shares, the short-interest ratio is currently 0.8 days.

enGene Price Performance

NASDAQ:ENGN traded up $0.08 during mid-day trading on Friday, reaching $3.82. 53,988 shares of the company were exchanged, compared to its average volume of 130,935. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $194.73 million, a PE ratio of -6.59 and a beta of -0.36. enGene has a 12 month low of $3.50 and a 12 month high of $15.74. The company has a fifty day moving average of $4.63 and a 200 day moving average of $6.48.

Analyst Ratings Changes

ENGN has been the subject of several recent research reports. Piper Sandler began coverage on enGene in a report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $25.00 target price on shares of enGene in a research note on Tuesday, March 11th. UBS Group downgraded shares of enGene from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $34.00 to $7.00 in a research note on Friday, February 14th. Morgan Stanley lowered their target price on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. Finally, JMP Securities restated a "market outperform" rating and set a $18.00 target price on shares of enGene in a research report on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $23.29.

Institutional Trading of enGene

Hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. lifted its holdings in enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after buying an additional 389,918 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of enGene during the fourth quarter worth $69,000. Blue Owl Capital Holdings LP raised its position in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock valued at $21,014,000 after acquiring an additional 101,006 shares during the period. Jane Street Group LLC acquired a new stake in enGene in the fourth quarter worth $93,000. Finally, Cubist Systematic Strategies LLC raised its stake in enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after buying an additional 2,080 shares during the period. 64.16% of the stock is owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.